Researchers have developed a pan-cancer patient-derived organoid (PDO) platform comprising 220 PDOs from 191 patients across 15 cancer types, advancing precision medicine by providing accurate models for evaluating cancer treatments. This development allows for the identification of new treatment candidates and could personalize therapy selection based on tumor characteristics, potentially expanding eligibility criteria for existing drugs like PARP inhibitors.
Read the full article at Genetic Engineering News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.
2
Ali NematiWritten by Ali
